AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Tuesday.
AZN has been the subject of a number of other reports. UBS Group reiterated a “neutral” rating and issued a GBX 5,600 ($73.17) target price on shares of AstraZeneca in a research note on Monday, July 2nd. Deutsche Bank lowered their target price on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a “buy” rating for the company in a research note on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, September 25th. Finally, Barclays set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Friday, July 27th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 5,705.70 ($74.56).
AZN stock opened at GBX 5,856 ($76.52) on Tuesday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Dividend
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.